BIRMF Q4 Results Management Briefing with Derek Webb, President and CEO of BIOREM

Key Takeaways

• Q4 revenue rose to $16.9M, up from $9.0M YoY
• Backlog topped $65M, highest on record
• Service unit booked $6.5M early 2026
• Middle East contributed $20M bookings despite conflict

Pulse Analysis

Biorem’s Q4 2025 results underscore the company’s ability to scale capital‑equipment sales while navigating the inherent lumpiness of large‑project pipelines. Revenue more than doubled year‑over‑year, and the full‑year earnings per share climbed to $0.26, reflecting tighter cost controls and higher utilization of its proprietary dry‑scrubber technology. The $65 million backlog—its strongest ever—provides a clear runway for continued top‑line growth, especially as the firm leverages its global manufacturing footprint to mitigate transportation and supply‑chain volatility that have rattled many peers.

A pivotal shift in Biorem’s strategy is the rapid build‑out of a dedicated service organization. By converting $26 million of deferred equipment bookings into $10 million of high‑margin service projects, the company has created a faster‑cash‑flow engine that can smooth revenue cycles. Early 2026 service bookings already total $6.5 million, and management points to a $200‑$300 million U.S. market for consumable dry‑scrubber adsorbents as a long‑term growth catalyst. This service focus not only boosts margins but also deepens customer relationships, driving the 99.99 % contract retention rate highlighted in the briefing.

Geopolitical exposure remains a nuanced factor. Biorem secured roughly $20 million in Middle‑East bookings over the past 12‑18 months and maintains active projects despite regional conflict, suggesting resilient demand from oil‑refinery customers. Coupled with a diversified manufacturing base in Canada and the United States, the firm is well‑positioned to absorb transportation cost spikes and other macro pressures. With a pipeline exceeding $100 million and a historically strong win rate—35 % overall and 52 % on public tenders—analysts can anticipate roughly $40 million of new revenue flowing in the next year, reinforcing Biorem’s earnings visibility and growth outlook.